Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $28
Benzinga Newsdesk 6 hours ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $25 to $28.
Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $25 to $28.